BRPI0610785A2 - polimorfo cristalino, processo para preparar o mesmo, forma cristalina, composição, e, métodos para tratar uma doença, distúrbios, e uma condição - Google Patents

polimorfo cristalino, processo para preparar o mesmo, forma cristalina, composição, e, métodos para tratar uma doença, distúrbios, e uma condição

Info

Publication number
BRPI0610785A2
BRPI0610785A2 BRPI0610785A BRPI0610785A BRPI0610785A2 BR PI0610785 A2 BRPI0610785 A2 BR PI0610785A2 BR PI0610785 A BRPI0610785 A BR PI0610785A BR PI0610785 A BRPI0610785 A BR PI0610785A BR PI0610785 A2 BRPI0610785 A2 BR PI0610785A2
Authority
BR
Brazil
Prior art keywords
disorders
disease
treating
preparing
composition
Prior art date
Application number
BRPI0610785A
Other languages
English (en)
Inventor
Abdolsamad Tadayon
Michel Bernatchez
Qing Yu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0610785A2 publication Critical patent/BRPI0610785A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
BRPI0610785A 2005-04-22 2006-04-21 polimorfo cristalino, processo para preparar o mesmo, forma cristalina, composição, e, métodos para tratar uma doença, distúrbios, e uma condição BRPI0610785A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67431805P 2005-04-22 2005-04-22
PCT/US2006/015309 WO2006116218A1 (en) 2005-04-22 2006-04-21 Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride

Publications (1)

Publication Number Publication Date
BRPI0610785A2 true BRPI0610785A2 (pt) 2016-09-13

Family

ID=36609610

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610785A BRPI0610785A2 (pt) 2005-04-22 2006-04-21 polimorfo cristalino, processo para preparar o mesmo, forma cristalina, composição, e, métodos para tratar uma doença, distúrbios, e uma condição

Country Status (13)

Country Link
US (1) US20060252825A1 (pt)
EP (1) EP1879875A1 (pt)
JP (1) JP2008538581A (pt)
CN (1) CN101163689A (pt)
AR (1) AR055054A1 (pt)
AU (1) AU2006239897A1 (pt)
BR (1) BRPI0610785A2 (pt)
CA (1) CA2603900A1 (pt)
GT (1) GT200600158A (pt)
MX (1) MX2007013179A (pt)
PE (1) PE20061319A1 (pt)
TW (1) TW200716583A (pt)
WO (1) WO2006116218A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
JP2008538576A (ja) * 2005-04-22 2008-10-30 ワイス クロマンおよびクロメン誘導体およびその使用
RU2007139543A (ru) * 2005-04-22 2009-05-27 Вайет (Us) Производные бензодиоксана и бензодиоксолана и их применение
PE20061318A1 (es) * 2005-04-22 2006-12-28 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
CA2604915A1 (en) * 2005-04-22 2006-11-02 Wyeth New therapeutic combinations for the treatment or prevention of depression
JP2008538573A (ja) * 2005-04-22 2008-10-30 ワイス ベンゾフラニルアルカナミン誘導体およびその５−ｈｔ２ｃアゴニストとしての使用
AU2006239920A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
AU2006239943A1 (en) * 2005-04-22 2006-11-02 Wyeth Treatment of pain
GT200600167A (es) * 2005-04-22 2007-03-14 Derivados de dihidrobenzofurano y usos de los mismos
AU2006239942A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
MX2007013064A (es) * 2005-04-24 2008-01-16 Wyeth Corp Metodo para modular la funcion de la vejiga.
EP2774925B1 (en) 2005-11-08 2016-12-28 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of ATP-binding cassette transporters
BRPI0709133A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp métodos para tratar distúrbios cognitivos e outros
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND ITS USE
HUE031913T2 (en) * 2007-12-07 2017-08-28 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
IT1397912B1 (it) * 2010-01-28 2013-02-04 Chemi Spa Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
RS62767B1 (sr) 2010-04-07 2022-01-31 Vertex Pharma Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
MX355183B (es) 2012-01-25 2018-04-09 Vertex Pharma Formulaciones de acido 3- (6- (1- (2.2- difluorobenzo [d] [1,3] dioxol-5-il) ciclopropancarboxamido) -3- metilpiridin-2-il) benzoico.
HRP20210516T2 (hr) 2013-11-12 2021-10-01 Vertex Pharmaceuticals Incorporated Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2554736A (en) * 1951-05-29 Tertiary aminoalkyl-iminodibenzyls
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US2005A (en) * 1841-03-16 Improvement in the manner of constructing molds for casting butt-hinges
US3513239A (en) * 1967-03-15 1970-05-19 Smithkline Corp Pharmaceutical compositions containing 2-aminoalkyl coumaran derivatives and methods of treating depression therewith
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
NL7503310A (nl) * 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4210754A (en) * 1977-02-01 1980-07-01 Hoffmann-La Roche Inc. Morpholino containing benzamides
US4205080A (en) * 1977-07-21 1980-05-27 Shell Oil Company 2,3-Dihydro benzofuran carboxamides
NL7906913A (nl) * 1979-09-17 1981-03-19 Tno Werkwijze en inrichting voor het tot stand brengen van een ionenstroom.
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4436371A (en) * 1981-06-24 1984-03-13 Donnelly Mirrors, Inc. Vehicle mirror assembly
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4992464A (en) * 1987-02-10 1991-02-12 Abbott Laboratories Heteroaryl N-hydroxy amides and ureas with polar substituents as 5-lipoxygenase inhibitors
US5212174A (en) * 1989-12-04 1993-05-18 G. D. Searle & Co. Quinoxalinyl/quinoxalinylakyl-N- terminal cycloalkoxy-C- terminal amino hydroxy β-amino acid derivatives
US5231111A (en) * 1989-12-04 1993-07-27 G. D. Searle & Co. Imidazolyl/imidazolylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives
US5212175A (en) * 1989-12-04 1993-05-18 G. D. Searle & Co. Benzothiophenyl benzothiophenylalkyl-N-terminal amino hydroxy β-amino acid derivatives
US5217988A (en) * 1989-12-04 1993-06-08 G. D. Searle & Co. Indolyl indolylakyl-N-terminal cycloalkoxy-C-terminal amino hydroxyβ-amino acid derivatives
US5223514A (en) * 1989-12-04 1993-06-29 G. D. Searle & Co. Quinolinyl/quinolinylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives
ATE118207T1 (de) * 1989-12-04 1995-02-15 Searle & Co Heterozyklische acylaminodiol-beta-aminosäure- derivate.
US5179102A (en) * 1989-12-04 1993-01-12 G. D. Searle & Co. Naphthyridinyl/naphthyridinylalkyl-n-terminal anino hydroxy β-amino acid derivatives
US5180725A (en) * 1989-12-04 1993-01-19 G. D. Searle & Co. Quinoxalinyl/quinoxaliy; alkyl-N-terminal amino hydroxy
US5180744A (en) * 1989-12-04 1993-01-19 G. D. Searle & Co. Aralkyl-N-terminal amino hydroxy
US5216013A (en) * 1989-12-04 1993-06-01 G. D. Searle & Co. Aralkyl-N-terminal cycloalkoxy-C terminal amino hydroxy β-amino acid derivatives
US5223512A (en) * 1989-12-04 1993-06-29 G. D. Searle & Co. Quinolonyl/quinolonylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives
US5175170A (en) * 1989-12-04 1992-12-29 G. D. Searle & Co. β-amino acid derivatives
US5210095A (en) * 1989-12-04 1993-05-11 G. D. Searle & Co. Chromonyl/chromonylalkyl-N-terminal amino hydroxy
US5223532A (en) * 1989-12-04 1993-06-29 G. D. Searle & Co. Chromonyl/chromonylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino derivatives
US5215996A (en) * 1989-12-04 1993-06-01 G. D. Searle & Co. Naphthyridinyl/naphthyridinylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives
US5217991A (en) * 1989-12-04 1993-06-08 G. D. Searle & Co. Cycloalkyl/cycloalkylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives
US5217989A (en) * 1989-12-04 1993-06-08 G. D. Searle & Co. Benothiophenyl/benzothiophenylalkyl-N-terminal cycloalkoxy-C-terminal amino hydroxy β-amino acid derivatives
US5110825A (en) * 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
RU2105005C1 (ru) * 1992-07-03 1998-02-20 Кумиай Кемикал Индастри Ко., Лтд. Конденсированное гетероциклическое производное, способ его получения и гербицидное средство
US5436246A (en) * 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
WO1994008962A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
US5712303A (en) * 1992-12-17 1998-01-27 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
ES2128544T3 (es) * 1992-12-17 1999-05-16 Pfizer Pirrolopirimidinas como antagonistas del crf.
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
US5292900A (en) * 1992-12-18 1994-03-08 Abbott Laboratories O-substituted N-hydroxyurea derivatives
ES2102195T3 (es) * 1992-12-28 1997-07-16 Eisai Co Ltd Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides.
PT1738753E (pt) * 1993-06-28 2008-06-19 Wyeth Corp Novos tratamentos utilizando derivados de fenetilamina
US5705646A (en) * 1993-09-30 1998-01-06 Pfizer Inc. Substituted pyrazoles as CRF antagonists
GB9408577D0 (en) * 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
CA2192928C (en) * 1994-06-15 2010-10-26 Hidenori Ogawa Benzoheterocyclic derivatives
CA2192815C (en) * 1994-07-07 1999-05-11 Yuji Kogami Novel 2,3-dihydrobenzofuran derivative, method for producing the same, and use thereof
US6150402A (en) * 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
PT707007E (pt) * 1994-10-14 2002-06-28 Merck Patent Gmbh Derivados amino(tio)eter como agentes activos no snc
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
AU6709896A (en) * 1995-08-21 1997-03-12 Takeda Chemical Industries Ltd. Quinone compound, its production and use
TW359669B (en) * 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
DK0880363T3 (da) * 1996-02-13 2003-01-20 Searle & Co Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
EP0971878B1 (en) * 1997-02-27 2008-03-26 Takeda Pharmaceutical Company Limited Amine compounds, their production and use as amyloid-beta production inhibitors
US6194407B1 (en) * 1997-07-30 2001-02-27 American Home Products Corporation Tricyclic pyrido vasopressin agonists
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6251936B1 (en) * 1998-05-12 2001-06-26 American Home Products Corporation Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
DK1087952T3 (da) * 1998-06-18 2004-10-04 Novartis Ag Banzazolforbindelser samt deres anvendelse
US6090803A (en) * 1998-07-24 2000-07-18 American Home Products Corporation Tricyclic vasopressin agonists
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US6255324B1 (en) * 1998-11-25 2001-07-03 Ned D. Heindel Amino-and mercurio-substituted 4′,5'-dihydropsoralens and therapeutical uses thereof
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6410562B1 (en) * 1998-12-18 2002-06-25 Eli Lilly And Company Hypoglycemic imidazoline compounds
US7045545B1 (en) * 1999-01-27 2006-05-16 Eli Lilly And Company Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists
AU2619800A (en) * 1999-01-27 2000-08-18 Eli Lilly And Company Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7217321B2 (en) * 2001-04-06 2007-05-15 California Institute Of Technology Microfluidic protein crystallography techniques
US7052545B2 (en) * 2001-04-06 2006-05-30 California Institute Of Technology High throughput screening of crystallization of materials
US7195670B2 (en) * 2000-06-27 2007-03-27 California Institute Of Technology High throughput screening of crystallization of materials
WO2002042731A2 (en) * 2000-11-20 2002-05-30 Parallel Synthesis Technologies, Inc. Methods and devices for high throughput crystallization
AR033095A1 (es) * 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
WO2003016276A2 (en) * 2001-08-14 2003-02-27 Eli Lilly And Company 3-substituted oxindole beta-3 agonists
CA2461381A1 (en) * 2001-10-04 2003-04-10 Wyeth Chroman derivatives as 5-hydroxytryptamine-6 ligands
US6569894B1 (en) * 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US20030105830A1 (en) * 2001-12-03 2003-06-05 Duc Pham Scalable network media access controller and methods
US20030134835A1 (en) * 2002-01-11 2003-07-17 Arthur Hancock Histamine-3 receptor ligands for diabetes conditions
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US6860940B2 (en) * 2002-02-11 2005-03-01 The Regents Of The University Of California Automated macromolecular crystallization screening
US20040009976A1 (en) * 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
AU2003291012A1 (en) * 2002-11-15 2004-06-15 Galileo Pharmaceuticals, Inc. Chroman derivatives for the reduction of inflammation symptoms
DE10341533A1 (de) * 2003-09-09 2005-03-31 Bayer Chemicals Ag Verfahren zur Herstellung von halogenhaltigen 4-Aminophenolen
US7728155B2 (en) * 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7516224B2 (en) * 2004-10-21 2009-04-07 Cisco Technology, Inc. Pseudowire termination directly on a router
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
US7593398B2 (en) * 2005-09-08 2009-09-22 Cisco Technology, Inc. Layer-two interworking applied to L2-L3 pseudowires
TW200815388A (en) * 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof

Also Published As

Publication number Publication date
MX2007013179A (es) 2008-01-16
AU2006239897A1 (en) 2006-11-02
PE20061319A1 (es) 2006-12-28
EP1879875A1 (en) 2008-01-23
CN101163689A (zh) 2008-04-16
JP2008538581A (ja) 2008-10-30
CA2603900A1 (en) 2006-11-02
WO2006116218A1 (en) 2006-11-02
GT200600158A (es) 2006-11-28
US20060252825A1 (en) 2006-11-09
TW200716583A (en) 2007-05-01
AR055054A1 (es) 2007-08-01
WO2006116218A8 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
BRPI0816904A2 (pt) Formas sólida, amorfa e cristalina, composição farmacêutica, e, método para tratar uma doença
BRPI0610693A2 (pt) métodos para tratamento de transtornos relacionados à ansiedade
BRPI0922566A2 (pt) polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
BRPI0814163A2 (pt) Processo para a preparação de compostos, forma cristalina, e, composição farmacêutica
BRPI0721502A2 (pt) Método para tratamento de uma formação fraturada
BRPI0807319A2 (pt) base de minociclina, base de miniciclina cristalizada, processo para preparar base de minociclina cristalina e processo para preparar base de minociclina amorfa.
BRPI0720068A2 (pt) Processo para preparar nanocápsulas, produto, nanocápsulas e composição
PT2351578T (pt) Processo para o fabrico de vacinas
BRPI0815784A2 (pt) Processo para a preparação de 1,2-propanodiol
BRPI0815611A2 (pt) Processo para sintetizar compostos úteis para tratar hepatite c
BRPI0820851A2 (pt) Processo para preparar microcápsulas
BRPI0819802A2 (pt) "composição fungicida, composto e método para controlar uma doença"
BRPI0613083A2 (pt) processo de alquilação para a produção de um aromático monolquilado
BRPI0812647A2 (pt) "composição e método para produzir a composição"
BRPI0807864A2 (pt) Complexo cristalino, processo para a preparação do complexo cristalino, e, composição agrícola
PT3415535T (pt) Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
BRPI0816911A2 (pt) Processo para preparação de 4-aminobut-2-enolidas
BRPI0815971A2 (pt) Processo para a preparação de 1,2-propanodiol
BRPI0811275A2 (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, uso de composto, e, método para tratar doença
BRPI1008987A2 (pt) processo para preparar 3,3,3-trifluoropropeno
BRPI0813960A2 (pt) Processo para produção de biarilas
BRPI0614727A2 (pt) processo para sintetizar uma peneira molecular
BRPI0819005A2 (pt) "processo para preparar cubos de tempero"
BRPI0912388A2 (pt) composto, forma cristalina, processo para preparar compostos, composição farmacêutica, e, uso de um composto, e, método para o tratamento ou profilaxia de doenças
BRPI0613574A2 (pt) forma cristalina isolada de um composto, método para preparar um composto, e, composição farmacêutica

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO 02007014840/RJ DE 19/10/2007.

B11M Dismissal: decision cancelled

Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.